cefalotin Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cephalothin is a first generation, semisynthetic analogue of natural cephalosporin antibiotic. The in-vitro bactericidal action of Cephalothin results from inhibition of cell-wall synthesis. In general, Cephalothin has higher activity against Gram positive than Gram negative organisms. Cephalothin is primarily indicated in conditions like bone and joint infection, genitourinary tract infections, respiratory tract infections, soft tissue and skin infections and others. The severe or irreversible adverse effects of Cephalothin, which give rise to further complications, include nephrotoxicity, hemolytic anemia. Cephalothin produces potentially life-threatening effects, which include anaphylaxis, serum sickness syndrome. The symptomatic adverse reactions produced by Cephalothin are: rashes, urticaria, allergic reactions, thrombophlebitis, pain at injection site. Co-administration of diuretics, such as furanthril, ethacrynic acid and nephrotoxic antibiotics may increase the risk of renal damage. Reciprocal inactivation could be observed during in vitro mixing of Cephalothin with aminoglycosides.   NCATS

Chemistry

  • SMILES: CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1
  • InChIKey: XIURVHNZVLADCM-IUODEOHRSA-N
  • Mol. Mass: 396.45
  • ALogP: 0.59
  • ChEMBL Molecules:
    cephalothin  
    cephalothin sodium  
More Chemistry

Pharmacology

Alternative names

38253 | 3-acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid | 7-(2-thienylacetamido)cephalosporanic acid | 7-(2'-thienylacetamido)cephalosporanic acid | 7-(thiophene-2-acetamido)cephalosporin | averon | cefalothin | cefalotin | cefalotina | cefalotine | cefalotin sodium | cefalotinum | cephalothin | cephalothin sodium | cephalothin sodium salt | cephalotin | cet | keflin | seffin | synclotin | toricelocin

Organizations (11)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (6)


 

Bone Diseases, Infectious (approved 1974)

Endocarditis (approved 1974)

Female Urogenital Diseases (approved 1974)

Respiratory Tract Infections (approved 1974)

Sepsis (approved 1974)

Staphylococcal Skin Infections (approved 1974)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Cystitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue